AstraZeneca PLC (AZN)vsVSee Health, Inc. (VSEE)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
VSEE
VSee Health, Inc.
$0.19
+2.22%
HEALTHCARE · Cap: $9.01M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 401721% more annual revenue ($58.74B vs $14.62M). AZN leads profitability with a 17.4% profit margin vs -100.6%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
VSEE
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for VSEE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -542.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : VSEE
The strongest argument for VSEE centers on Debt/Equity.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : VSEE
The primary concerns for VSEE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while VSEE is a turnaround play — different risk/reward profiles.
VSEE carries more volatility with a beta of 0.65 — expect wider price swings.
VSEE is growing revenue faster at 5.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 32/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
VSee Health, Inc.
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
VSee Health, Inc. is a leading innovator in the telehealth sector, offering secure, user-friendly video communication solutions tailored for healthcare providers and patients. Its comprehensive platform encompasses a range of functionalities such as remote patient monitoring, asynchronous messaging, and seamless electronic medical record (EMR) interoperability, all designed to enhance the efficiency and quality of healthcare delivery across various specialties. With a strong commitment to improving patient engagement and accessibility, VSee caters to a diverse global clientele, positioning itself to capitalize on the growing demand for virtual care in the evolving healthcare landscape. As the industry shifts towards digital solutions, VSee Health is poised for significant growth through its cutting-edge technology and strategic initiatives.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?